Thursday, 20 January, 2022 - 15:00
Euroz backs Australian pharma
A pharmaceutical company specialising in the treatment of common colds and viral diseases will list on the ASX this month, having raised $7 million through an IPO.
Stephen Goodall
Co-Founder, Director, Chief Operating Officer / Firebrick Pharma
Stephen Goodall has extensive experience in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He also has extensive experience in the pre-clinical, IND, regulatory and human clinical phases of drug development.
Dr Goodall is the co-founder and chief operating officer of Firebrick Pharma, which is awaiting the approval of a nasal spray medicine that targets the cause of colds. Prior to that, he was the chief operating officer of Viralytics, which was later acquired in 2018 for $500 million by the US big pharma company, Merck. Dr Goodall was also the director of pharmaceutical development at Vapotronics, where he managed all aspects of inhaled drug development and formulation; and a director of development at AGEN Biomedical.
